- Home
- AKYA vs HLVX Comparison
AKYA vs HLVX Comparison
Compare AKYA & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKYA
- HLVX
- Stock Information
- Founded
- AKYA 2015
- HLVX 2020
- Country
- AKYA United States
- HLVX United States
- Employees
- AKYA N/A
- HLVX N/A
- Industry
- AKYA Medical Specialities
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- AKYA Industrials
- HLVX Health Care
- Exchange
- AKYA Nasdaq
- HLVX Nasdaq
- Market Cap
- AKYA 84.7M
- HLVX 83.7M
- IPO Year
- AKYA 2021
- HLVX 2022
- Fundamental
- Price
- AKYA $1.35
- HLVX $1.39
- Analyst Decision
- AKYA Buy
- HLVX Hold
- Analyst Count
- AKYA 7
- HLVX 5
- Target Price
- AKYA $3.26
- HLVX $2.33
- AVG Volume (30 Days)
- AKYA 251.7K
- HLVX 144.6K
- Earning Date
- AKYA 05-12-2025
- HLVX 03-28-2025
- Dividend Yield
- AKYA N/A
- HLVX N/A
- EPS Growth
- AKYA N/A
- HLVX N/A
- EPS
- AKYA N/A
- HLVX N/A
- Revenue
- AKYA $81,672,000.00
- HLVX N/A
- Revenue This Year
- AKYA $13.94
- HLVX N/A
- Revenue Next Year
- AKYA $14.48
- HLVX N/A
- P/E Ratio
- AKYA N/A
- HLVX N/A
- Revenue Growth
- AKYA N/A
- HLVX N/A
- 52 Week Low
- AKYA $1.32
- HLVX $1.37
- 52 Week High
- AKYA $4.65
- HLVX $16.31
- Technical
- Relative Strength Index (RSI)
- AKYA 29.49
- HLVX 17.95
- Support Level
- AKYA $1.32
- HLVX $1.70
- Resistance Level
- AKYA $1.78
- HLVX $1.71
- Average True Range (ATR)
- AKYA 0.14
- HLVX 0.08
- MACD
- AKYA 0.01
- HLVX -0.03
- Stochastic Oscillator
- AKYA 6.52
- HLVX 3.41
About AKYA Akoya BioSciences Inc.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.